The effect of drugs on serum histidine levels in rheumatoid arthritis

Dixon, Jonathan S.; Sitton, N. G.; Surrall, K. E.; Martin, M. F. R.; Pickup, M. E.; Bird, H. A.

doi:10.1007/bf00541592

Cited by 7 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, we were unable to collect information regarding the types and doses of lipid-lowering drugs. Nevertheless, previous studies have reported that commonly used lipid-lowering drugs showed similar effects on KOA 33 – 35 . Third, we did not collect information regarding dietary patterns and were unable to evaluate the possible confounding influence of this factor.…”

Section: Discussionmentioning

confidence: 93%

The cross-sectional and longitudinal effect of hyperlipidemia on knee osteoarthritis: Results from the Dongfeng-Tongji cohort in China

Zhou

Guo

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

To quantify the cross-sectional and longitudinal effects of hyperlipidemia on knee osteoarthritis (KOA), we studied 13,906 middle-aged or older participants from the Dongfeng-Tongji cohort. Physical examinations were performed at baseline and follow-up. Knee pain was diagnosed by self-reported pain or stiffness. Clinical KOA was diagnosed from knee pain complains and clinical X-ray radiographs. The prevalence of knee pain and clinical KOA was 39.0% and 6.7% at baseline, respectively. Hyperlipidemia was associated with knee pain (OR 1.34, 1.23–1.45) and clinical KOA (1.34, 1.15–1.55). Compared with the participants without hyperlipidemia or use of lipid-lowering drugs, those with hyperlipidemia but no use of lipid-lowering drugs had higher risks of knee pain (1.28, 1.15–1.43) and clinical KOA (1.20, 0.97–1.48), those with hyperlipidemia and use of lipid-lowering drugs had the highest risks of knee pain (1.40, 1.26–1.56) and clinical KOA (1.45, 1.21–1.75). The risks were not elevated among participants without hyperlipidemia but using lipid-lowering drugs for prevention of other diseases. Furthermore, each 1-unit increase in triglyceride was associated with 9% and 5% increases in the risk of clinical KOA prevalence and clinical KOA onset, respectively. In conclusion, hyperlipidemia is associated with elevated risks of knee pain and clinical KOA among middle-aged or older adults.

show abstract

Section: Discussionmentioning

confidence: 93%

The cross-sectional and longitudinal effect of hyperlipidemia on knee osteoarthritis: Results from the Dongfeng-Tongji cohort in China

Zhou

Guo

Wang

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Reduced glycine and histidine in OA cartilage samples have been reported in metabolomics analyses using high-resolution nuclear magnetic resonance spectroscopy [ 14 – 16 ], and serum valine to histidine and leucine to histidine ratios have been proposed to be potential biomarkers for the management of OA [ 17 ]. In addition, reduced urinary glycine and histidine levels were also found to be associated with a poor response to methotrexate treatment in a collagen-induced arthritis animal model [ 18 ]. Taken together, evidence strongly suggests that glycine and histidine as well as their relevant metabolic pathways may undergo pathological alterations during the development of OA.…”

Section: Discussionmentioning

confidence: 99%

Serum Metabolites as Potential Biomarkers for Diagnosis of Knee Osteoarthritis

Zhang

et al. 2015

Disease Markers

View full text Add to dashboard Cite

Knee osteoarthritis (OA) is a highly prevalent chronic degenerative joint disease that mainly affects the elderly population. The aim of this study was to investigate serum signature metabolites as potential biomarkers for early diagnosis of knee OA. Global serum metabolic profiles of 40 patients with knee OA and 20 healthy controls (HC) were analyzed by ultra-performance liquid chromatography coupled to mass spectrometry. An OA-specific metabolic profile was established that can clearly discriminate patients with OA from HCs. Fourteen metabolites that are involved in the metabolism of amino acids, purine, energy, glycolysis, fatty acids, and lipids were significantly altered in patients with OA compared to HCs. These metabolites could be potentially used as biomarkers for the diagnosis of knee OA.

show abstract

“…fibrate treatment in patients with RA, while in the study by Goto, fibrates had no effect [McConkey et al 1980;Goto, 2010]. Bird and colleagues demonstrated a significant reduction in CRP and ESR after treating patients with RA with 300 mg clofibrate, which was also shown by Dixon and colleagues for CRP [Bird et al 1983;Dixon et al 1983]. Reynolds and colleagues reported a nonsignificant reduction in CRP and ESR levels [Reynolds et al 1981].…”

Section: Reduction Of Systemic Inflammatory Parametersmentioning

confidence: 92%

“…Dixon and colleagues and Bird and colleagues reported a significant improvement in the articular index [Ritchie et al 1969] and early morning stiffness after treatment with 300 mg clobuzarit. This reduction was not seen with 100 mg clobuzarit [Bird et al 1983;Dixon et al 1983]. Bird and colleagues also showed a significant improvement in grip strength when 100 mg or 300 mg clobuzarit was given, which was not seen in the study by Dixon and colleagues [Bird et al 1983;Dixon et al 1983].…”

Section: Clinical Effectsmentioning

confidence: 97%

“…This reduction was not seen with 100 mg clobuzarit [Bird et al 1983;Dixon et al 1983]. Bird and colleagues also showed a significant improvement in grip strength when 100 mg or 300 mg clobuzarit was given, which was not seen in the study by Dixon and colleagues [Bird et al 1983;Dixon et al 1983]. Reynolds and colleagues found no improvement in all assessments of function after the use of 50 mg clobuzarit [Reynolds et al 1981].…”

Section: Clinical Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review

Eekeren

Clockaerts

Bastiaansen-Jenniskens

et al. 2013

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Fibrates are used as lipid-lowering drugs to prevent cardiovascular pathology. Fibrates are ligands of peroxisome proliferator-activated receptor α (PPARα). Besides altering lipid metabolism, PPARα ligands exert anti-inflammatory effects on various cell types. In this study, we hypothesized that PPARα agonists exert beneficial effects on osteoarthritis (OA) and rheumatoid arthritis (RA) by their local anti-inflammatory effects, but also by their systemic influences. A systematic literature search of Medline and EMBASE databases was performed up to August 2011. The main search items were osteoarthritis, rheumatoid arthritis, peroxisome proliferator-activated receptor alpha and fibrates. Inclusion criteria were in vivo or in vitro studies regarding humans or animals in which the effects of PPARα ligands were studied. Six in vivo human studies, four in vivo animal studies and seven in vitro studies were included. The in vivo human studies showed all beneficial clinical effects of PPARα ligands, but studies were small and only four were randomized. Ligands for PPARα significantly reduced pain, swelling of the joints and decreased systemic inflammatory markers. In vitro and in vivo animal studies indicate that PPARα agonists inhibit bone resorption, and reduce inflammatory and destructive responses in cartilage and synovium. PPARα agonists such as fibrates should be considered as potential therapeutic strategy for RA. There is no clinical evidence for their use in OA, although in vitro studies indicate that PPARα agonists demonstrate different joint-protective effects locally, and systemic effects on inflammation, serum lipid levels and vascular pathology. Animal studies should be performed and after confirmation of the protective effects of PPARα, large randomized controlled trials could investigate fibrates in OA and RA.

show abstract

The effect of drugs on serum histidine levels in rheumatoid arthritis

Cited by 7 publications

References 19 publications

The cross-sectional and longitudinal effect of hyperlipidemia on knee osteoarthritis: Results from the Dongfeng-Tongji cohort in China

The cross-sectional and longitudinal effect of hyperlipidemia on knee osteoarthritis: Results from the Dongfeng-Tongji cohort in China

Serum Metabolites as Potential Biomarkers for Diagnosis of Knee Osteoarthritis

Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review

Contact Info

Product

Resources

About